IM-1021

Antibody–drug conjugate

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

Company guidance: data expected in 2026 (Immunome, Inc., 9 Nov 2026). “In November 2025, we reported observed objective responses at multiple dose levels in B-cell lymphoma patients treated with IM-1021, and we plan to share initial data in 2026.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (1)
Other / comorbidity

Competitive landscape

1 other tracked programme targets this mechanism, 1 of them ahead of this one.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
IM-1021: this drugPhase 1Antibody–drug conjugateROR1not yet gradedNo reviewed efficacy summary
Zilovertamab Vedotin
Phase 2/3(overall)
Antibody–drug conjugateROR1not yet gradedNo reviewed efficacy summary

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow IM-1021 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
May 2028 (1)
Phase 1Solid Malignancies, Hematologic MalignanciesRecruiting
Est. primary completion 2028-05 · NCT06823167 · CT.gov ↗
What to watch

See the full readout calendar ↗